EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma

Phase 2 ◽

First Line ◽

First Line Therapy ◽

Phase 2 Trial ◽

P0211 EVERSUN: A phase 2 trial of everolimus alternating with sunitinib as first-line therapy for advanced renal cell carcinoma (ANZUP Trial 0901)

European Journal of Cancer ◽

10.1016/j.ejca.2014.03.255 ◽

2014 ◽

Vol 50 ◽

pp. e68-e69

Author(s):

I.D. Davis ◽

A. Long ◽

A. Martin ◽

D. Espinoza ◽

S. Yip ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Phase 2 ◽

First Line ◽

First Line Therapy ◽

Phase 2 Trial ◽

PCASE1 UTILIZING EVIDENCE FROM DIFFERENT LEVELS IN THE REIMBURSEMENT PROCESS OF NEW MEDICAL TECHNOLOGIES-ADVANCED RENAL CELL CARCINOMA FIRST LINE THERAPY IN POLAND 2008-2009

Value in Health ◽

10.1016/s1098-3015(10)73062-x ◽

2010 ◽

Vol 13 (3) ◽

pp. A217

Author(s):

W Matusewicz ◽

J Baran ◽

MM Farkowski

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

First Line ◽

Medical Technologies ◽

First Line Therapy ◽

Line Therapy ◽

Different Levels

First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis

Cochrane Database of Systematic Reviews ◽

10.1002/14651858.cd013798 ◽

2020 ◽

Author(s):

Marius Goldkuhle ◽

Angela Aldin ◽

Tina Jakob ◽

Anne Adams ◽

Ina Monsef ◽

...

Keyword(s):

Systematic Review ◽

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Meta Analysis ◽

First Line ◽

First Line Therapy ◽

Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma

Journal for ImmunoTherapy of Cancer ◽

10.1186/s40425-018-0440-9 ◽

2018 ◽

Vol 6 (1) ◽

Cited By ~ 20

Author(s):

Bin Wu ◽

Qiang Zhang ◽

Jie Sun

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Renal Cell ◽

First Line ◽

First Line Therapy ◽

The European Commission has granted approval for temsirolimus [Torisel; Wyeth Pharmaceuticals] within the EU as first-line therapy in patients with advanced renal cell carcinoma

Inpharma Weekly ◽

10.2165/00128413-200716160-00065 ◽

2007 ◽

Vol &NA; (1616) ◽

pp. 27

Author(s):

&NA;

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

European Commission ◽

Renal Cell ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

The Eu

P0201 Circulating biomarkers and outcomes in a phase 2 trial of first-line everolimus alternating with sunitinib for advanced renal cell carcinoma (ANZUP 0901—the EVERSUN Trial)

European Journal of Cancer ◽

10.1016/j.ejca.2014.03.245 ◽

2014 ◽

Vol 50 ◽

pp. e65

Author(s):

S. Yip ◽

N. Pavlakis ◽

R. Harvie ◽

A. Martin ◽

A. Hudson ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Phase 2 ◽

Circulating Biomarkers ◽

First Line ◽

Phase 2 Trial

Phase II study of pazopanib plus interferon alfa as first-line therapy of advanced renal cell carcinoma: A Spanish Oncology Genitourinary Group (SOGUG) study.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.4571 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 4571-4571

Author(s):

Xavier Garcia del Muro ◽

Miguel Angel Climent ◽

Jose Luis Perez-Gracia ◽

Begona Mellado ◽

JA Virizuela ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Renal Cell ◽

Phase Ii Study ◽

Interferon Alfa ◽

First Line ◽

First Line Therapy ◽

7154 POSTER Hypothyroidism and Macrocytosis as Surrogate Markers for Response and Survival in Patients With Advanced Renal Cell Carcinoma Treated With Sunitinib as First-line Therapy

European Journal of Cancer ◽

10.1016/s0959-8049(11)72069-x ◽

2011 ◽

Vol 47 ◽

pp. S521 ◽

Cited By ~ 1

Author(s):

A. Pinto ◽

V. Moreno ◽

C. Aguayo ◽

M. Garrido ◽

E. Espinosa

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Surrogate Markers ◽

First Line ◽

First Line Therapy ◽

Persistence and Compliance Among U.S. Patients Receiving Pazopanib or Sunitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: A Retrospective Claims Analysis

Journal of Managed Care & Specialty Pharmacy ◽

10.18553/jmcp.2015.21.6.515 ◽

2015 ◽

Vol 21 (6) ◽

pp. 515-522 ◽

Cited By ~ 6

Author(s):

Stacey A. DaCosta Byfield ◽

Jeffrey T. McPheeters ◽

Tanya M. Burton ◽

Saurabh P. Nagar ◽

Michelle D. Hackshaw

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Claims Analysis ◽

First Line ◽

First Line Therapy ◽

Cost‐Effectiveness of Pembrolizumab plus Axitinib Versus Sunitinib as First‐Line Therapy in Advanced Renal Cell Carcinoma in the U.S.

The Oncologist ◽

10.1002/onco.13522 ◽

2020 ◽

Author(s):

Dong Ding ◽

Huabin Hu ◽

Yin Shi ◽

Longjiang She ◽

Linli Yao ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Renal Cell ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

The U.S